Clinical Trials Logo

Bladder Mixed Adenocarcinoma clinical trials

View clinical trials related to Bladder Mixed Adenocarcinoma.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03912818 Terminated - Clinical trials for Bladder Urothelial Carcinoma

Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer

Start date: April 10, 2019
Phase: Phase 2
Study type: Interventional

This phase II trial studies the side effects of durvalumab and chemotherapy before surgery in treating patients with variant histology bladder cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as methotrexate, vinblastine, doxorubicin, cisplatin, gemcitabine, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving durvalumab in addition to standard chemotherapy may lead to better outcomes in patients with variant histology bladder cancer.